Logo image of SYRA

SYRA HEALTH CORP - CLASS A (SYRA) Stock Fundamental Analysis

NASDAQ:SYRA - Nasdaq - US87168W2035 - Common Stock - Currency: USD

0.1043  -0.02 (-17.94%)

After market: 0.0805 -0.02 (-22.82%)

Fundamental Rating

2

Taking everything into account, SYRA scores 2 out of 10 in our fundamental rating. SYRA was compared to 102 industry peers in the Health Care Providers & Services industry. SYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SYRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SYRA had negative earnings in the past year.
SYRA had a negative operating cash flow in the past year.
SYRA had negative earnings in each of the past 5 years.
SYRA had a negative operating cash flow in each of the past 5 years.
SYRA Yearly Net Income VS EBIT VS OCF VS FCFSYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

The Return On Assets of SYRA (-102.17%) is worse than 94.29% of its industry peers.
SYRA's Return On Equity of -130.59% is on the low side compared to the rest of the industry. SYRA is outperformed by 80.95% of its industry peers.
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROIC N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYRA Yearly ROA, ROE, ROICSYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Gross Margin of SYRA (20.71%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SYRA has declined.
SYRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
SYRA Yearly Profit, Operating, Gross MarginsSYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

4

2. Health

2.1 Basic Checks

SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SYRA has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SYRA is higher compared to a year ago.
SYRA Yearly Shares OutstandingSYRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly Total Debt VS Total AssetsSYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

SYRA has an Altman-Z score of -2.79. This is a bad value and indicates that SYRA is not financially healthy and even has some risk of bankruptcy.
SYRA has a worse Altman-Z score (-2.79) than 85.71% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that SYRA is not too dependend on debt financing.
SYRA has a better Debt to Equity ratio (0.05) than 78.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC8.73%
SYRA Yearly LT Debt VS Equity VS FCFSYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
SYRA's Current ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
A Quick Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.46, SYRA belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.46
SYRA Yearly Current Assets VS Current LiabilitesSYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

3

3. Growth

3.1 Past

SYRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.98%.
The Revenue has grown by 44.67% in the past year. This is a very strong growth!
Measured over the past years, SYRA shows a very strong growth in Revenue. The Revenue has been growing by 78.22% on average per year.
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYRA Yearly Revenue VS EstimatesSYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly EPS VS EstimatesSYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRA Price Earnings VS Forward Price EarningsSYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRA Per share dataSYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYRA HEALTH CORP - CLASS A

NASDAQ:SYRA (4/17/2025, 8:00:00 PM)

After market: 0.0805 -0.02 (-22.82%)

0.1043

-0.02 (-17.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners6.21%
Inst Owner Change-69.74%
Ins Owners0.62%
Ins Owner Change0%
Market Cap1.18M
AnalystsN/A
Price Target1.84 (1664.14%)
Short Float %2.94%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)9.8%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.71
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.71%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
F-Score4
Asset Turnover2.17
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.7%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 5.46
Altman-Z -2.79
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)287.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.27%
OCF growth 3YN/A
OCF growth 5YN/A